Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Positron emission tomography imaging with 18F-labeled ZHER2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies.

Trousil S, Hoppmann S, Nguyen QD, Kaliszczak M, Tomasi G, Iveson P, Hiscock D, Aboagye EO.

Clin Cancer Res. 2014 Mar 15;20(6):1632-43. doi: 10.1158/1078-0432.CCR-13-2421. Epub 2014 Feb 3.

2.

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.

Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V, Boerman OC.

J Nucl Med. 2012 Jan;53(1):146-53. doi: 10.2967/jnumed.111.093047. Epub 2011 Dec 15.

3.

PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].

4.

Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.

Rosik D, Thibblin A, Antoni G, Honarvar H, Strand J, Selvaraju RK, Altai M, Orlova A, Eriksson Karlström A, Tolmachev V.

Bioconjug Chem. 2014 Jan 15;25(1):82-92. doi: 10.1021/bc400343r. Epub 2013 Dec 27.

PMID:
24344772
5.

Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.

Kramer-Marek G, Kiesewetter DO, Capala J.

J Nucl Med. 2009 Jul;50(7):1131-9. doi: 10.2967/jnumed.108.057695. Epub 2009 Jun 12.

6.

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

Orlova A, Wållberg H, Stone-Elander S, Tolmachev V.

J Nucl Med. 2009 Mar;50(3):417-25. doi: 10.2967/jnumed.108.057919. Epub 2009 Feb 17.

7.

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.

8.

Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.

Glaser M, Iveson P, Hoppmann S, Indrevoll B, Wilson A, Arukwe J, Danikas A, Bhalla R, Hiscock D.

J Nucl Med. 2013 Nov;54(11):1981-8. doi: 10.2967/jnumed.113.122465. Epub 2013 Oct 10.

9.

[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.

Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J.

Eur J Nucl Med Mol Imaging. 2008 May;35(5):1008-18. Epub 2007 Dec 22.

10.

(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.

Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, Jong JR, Dongen GA, Jensen MR, Quadt C, Hooge MN, Vries EG.

Eur J Cancer. 2010 Feb;46(3):678-84. doi: 10.1016/j.ejca.2009.12.009. Epub 2009 Dec 24.

PMID:
20036116
11.

68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.

Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1967-76. doi: 10.1007/s00259-011-1810-4. Epub 2011 Apr 20.

12.

Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry.

Namavari M, Padilla De Jesus O, Cheng Z, De A, Kovacs E, Levi J, Zhang R, Hoerner JK, Grade H, Syud FA, Gambhir SS.

Mol Imaging Biol. 2008 Jul-Aug;10(4):177-81. doi: 10.1007/s11307-008-0142-7. Epub 2008 May 15.

13.

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V.

J Nucl Med. 2013 Jun;54(6):961-8. doi: 10.2967/jnumed.112.110700. Epub 2013 Mar 25.

14.

Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.

Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A, Cheng Z.

Bioconjug Chem. 2011 Mar 16;22(3):413-21. doi: 10.1021/bc100432h. Epub 2011 Feb 7.

15.

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.

McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM.

J Nucl Med. 2009 Aug;50(8):1340-8. doi: 10.2967/jnumed.109.062224. Epub 2009 Jul 17.

16.

Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.

Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, Tolmachev V.

J Nucl Med. 2006 Mar;47(3):512-9.

17.

A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.

Miao Z, Ren G, Jiang L, Liu H, Webster JM, Zhang R, Namavari M, Gambhir SS, Syud F, Cheng Z.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1977-84. doi: 10.1007/s00259-011-1879-9. Epub 2011 Jul 15.

18.

Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).

Zhang J, Zhao X, Wang S, Wang N, Han J, Jia L, Ren X.

Nucl Med Biol. 2015 Jun;42(6):541-6. doi: 10.1016/j.nucmedbio.2015.02.002. Epub 2015 Feb 11.

PMID:
25735223
19.

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.

J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16.

20.

Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.

Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, Gambhir SS.

J Nucl Med. 2008 May;49(5):804-13. doi: 10.2967/jnumed.107.047381. Epub 2008 Apr 15.

Supplemental Content

Support Center